VIR PE Ratio & Valuation,Is VIR Overvalued

VIR Relative Valuation

VIR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VIR is overvalued; if below, it's undervalued.

Historical Valuation

Vir Biotechnology Inc (VIR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 110.14 is considered Overvalued compared with the five-year average of -6.16. The fair price of Vir Biotechnology Inc (VIR) is between 2.30 to 4.70 according to relative valuation methord. Compared to the current price of 6.69 USD , Vir Biotechnology Inc is Overvalued By 42.31%.

Relative Value

Fair Zone

2.30-4.70

Current Price：6.69

42.31%

Overvalued

-2.74

-1.18

EV/EBITDA

Vir Biotechnology Inc. (VIR) has a current EV/EBITDA of -1.18. The 5-year average EV/EBITDA is -2.61. The thresholds are as follows: Strongly Undervalued below -27.18, Undervalued between -27.18 and -14.90, Fairly Valued between 9.67 and -14.90, Overvalued between 9.67 and 21.95, and Strongly Overvalued above 21.95. The current Forward EV/EBITDA of -1.18 falls within the Historic Trend Line -Fairly Valued range.

-1.09

EV/EBIT

Vir Biotechnology Inc. (VIR) has a current EV/EBIT of -1.09. The 5-year average EV/EBIT is -4.81. The thresholds are as follows: Strongly Undervalued below -39.70, Undervalued between -39.70 and -22.26, Fairly Valued between 12.63 and -22.26, Overvalued between 12.63 and 30.07, and Strongly Overvalued above 30.07. The current Forward EV/EBIT of -1.09 falls within the Historic Trend Line -Fairly Valued range.

110.14

Vir Biotechnology Inc. (VIR) has a current PS of 110.14. The 5-year average PS is 27.01. The thresholds are as follows: Strongly Undervalued below -22.46, Undervalued between -22.46 and 2.28, Fairly Valued between 51.74 and 2.28, Overvalued between 51.74 and 76.47, and Strongly Overvalued above 76.47. The current Forward PS of 110.14 falls within the Strongly Overvalued range.

-2.71

P/OCF

Vir Biotechnology Inc. (VIR) has a current P/OCF of -2.71. The 5-year average P/OCF is 5.01. The thresholds are as follows: Strongly Undervalued below -76.59, Undervalued between -76.59 and -35.79, Fairly Valued between 45.80 and -35.79, Overvalued between 45.80 and 86.60, and Strongly Overvalued above 86.60. The current Forward P/OCF of -2.71 falls within the Historic Trend Line -Fairly Valued range.

-2.22

P/FCF

Vir Biotechnology Inc. (VIR) has a current P/FCF of -2.22. The 5-year average P/FCF is 7.56. The thresholds are as follows: Strongly Undervalued below -84.46, Undervalued between -84.46 and -38.45, Fairly Valued between 53.57 and -38.45, Overvalued between 53.57 and 99.57, and Strongly Overvalued above 99.57. The current Forward P/FCF of -2.22 falls within the Historic Trend Line -Fairly Valued range.

Vir Biotechnology Inc (VIR) has a current Price-to-Book (P/B) ratio of 1.17. Compared to its 3-year average P/B ratio of 1.01 , the current P/B ratio is approximately 15.93% higher. Relative to its 5-year average P/B ratio of 2.63, the current P/B ratio is about -55.54% higher. Vir Biotechnology Inc (VIR) has a Forward Free Cash Flow (FCF) yield of approximately -49.42%. Compared to its 3-year average FCF yield of -33.69%, the current FCF yield is approximately 46.69% lower. Relative to its 5-year average FCF yield of -15.57% , the current FCF yield is about 217.34% lower.

1.17

P/B

Median3y

1.01

Median5y

2.63

-49.42

FCF Yield

Median3y

-33.69

Median5y

-15.57

Competitors Valuation Multiple

The average P/S ratio for VIR's competitors is 156.52, providing a benchmark for relative valuation. Vir Biotechnology Inc Corp (VIR) exhibits a P/S ratio of 110.14, which is -29.63% above the industry average. Given its robust revenue growth of -89.92%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of VIR decreased by 8.86% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -8.98K to -67.98K.

The secondary factor is the Revenue Growth, contributed -89.92%to the performance.

Overall, the performance of VIR in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-89.92%

2.38M → 240.00K

Revenue Growth

656.99%

-8.98K → -67.98K

Margin Expansion

-575.93%

0.39 → -1.85

P/E Change

-8.86%

7.34 → 6.69

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Vir Biotechnology Inc (VIR) currently overvalued or undervalued?

What is Vir Biotechnology Inc (VIR) fair value?

VIR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Vir Biotechnology Inc (VIR) is between 2.30 to 4.70 according to relative valuation methord.

How does VIR's valuation metrics compare to the industry average?

What is the current P/B ratio for Vir Biotechnology Inc (VIR) as of Dec 15 2025?

As of Dec 15 2025, Vir Biotechnology Inc (VIR) has a P/B ratio of 1.17. This indicates that the market values VIR at 1.17 times its book value.

What is the current FCF Yield for Vir Biotechnology Inc (VIR) as of Dec 15 2025?

As of Dec 15 2025, Vir Biotechnology Inc (VIR) has a FCF Yield of -49.42%. This means that for every dollar of Vir Biotechnology Inc’s market capitalization, the company generates -49.42 cents in free cash flow.

What is the current Forward P/E ratio for Vir Biotechnology Inc (VIR) as of Dec 15 2025?

As of Dec 15 2025, Vir Biotechnology Inc (VIR) has a Forward P/E ratio of -2.74. This means the market is willing to pay $-2.74 for every dollar of Vir Biotechnology Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Vir Biotechnology Inc (VIR) as of Dec 15 2025?

As of Dec 15 2025, Vir Biotechnology Inc (VIR) has a Forward P/S ratio of 110.14. This means the market is valuing VIR at $110.14 for every dollar of expected revenue over the next 12 months.

VIR Valuation